Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹230 Cr.
Stock P/E
22.1
P/B
3
Current Price
₹199
Book Value
₹ 65.2
Face Value
10
52W High
₹210
52W Low
₹ 77
Dividend Yield
0.5%

Resonance Specialtie Overview

Business

Resonance Specialties Ltd. is an Indian specialty chemicals manufacturer. The company primarily focuses on the production of Piperazine and its derivatives, along with various polymer additives and other tailor-made specialty chemicals. Its core business model is B2B (Business-to-Business), supplying these chemical intermediates and additives to a diverse range of industries including pharmaceuticals, agrochemicals, plastics, textiles, and other industrial applications. The company makes money by manufacturing and selling these specialized chemical products, leveraging its technical expertise and manufacturing capabilities.

Revenue Mix

While a granular segment breakdown with specific revenue percentages is not always publicly detailed for all Indian specialty chemical companies, Resonance Specialties primarily operates across the following product categories:

Piperazine and its Derivatives: A significant focus, catering to pharmaceutical, agrochemical, and other specialty chemical industries.

Polymer Additives: Such as antioxidants and UV stabilizers, essential for the plastics and polymer industries.

Other Specialty Chemicals: Often custom-synthesized products for specific industrial requirements.

The revenue is derived from the sales of these manufactured products to industrial clients.

Industry

Resonance Specialties operates within the broad Indian Chemicals sector, specifically the Specialty Chemicals industry. This industry is characterized by high growth potential, driven by domestic demand and export opportunities, and typically involves specialized manufacturing processes and application-specific products. Resonance is positioned as a niche player, particularly known for its expertise in Piperazine chemistry. It competes with both domestic and international specialty chemical manufacturers. Its positioning relies on product quality, adherence to specific customer requirements, and technical know-how in its chosen product areas, rather than broad commodity chemical production.

MOAT

Resonance Specialties' competitive advantages likely stem from:

Niche Expertise & Product Specialization: Deep technical knowledge and experience in manufacturing complex chemicals like Piperazine derivatives create entry barriers for new competitors. This allows them to cater to specific, high-value applications.

Customer Relationships & Switching Costs: For specialty chemicals, customers often require specific grades and quality, leading to long-term relationships and higher switching costs once a supplier is approved and integrated into their supply chain.

Process Know-how: Proprietary manufacturing processes or optimized production methods can lead to cost efficiencies and consistent product quality, differentiating them from competitors.

Growth Drivers

Growing End-User Industries: Increased demand from key client sectors like pharmaceuticals, agrochemicals, and plastics drives the need for specialty chemical intermediates and additives.

Rising Demand for Specialty Chemicals: Global shift towards higher-value, application-specific specialty chemicals, moving away from commoditized bulk chemicals.

Capacity Expansion: Any planned or ongoing expansion projects to meet growing demand and diversify product offerings.

Product Diversification & Innovation: Development of new products or grades to capture emerging market opportunities and serve new applications.

Export Market Growth: Leveraging India's competitive manufacturing costs and global supply chain realignments to increase export penetration.

Risks

Raw Material Price Volatility: Dependence on crude oil derivatives or other commodity chemicals as inputs makes the company susceptible to price fluctuations, impacting profitability.

Intense Competition: Competition from both domestic and international players can lead to pricing pressures and margin erosion.

Regulatory & Environmental Changes: Strict environmental norms, safety regulations, and other government policies can increase operational costs, require significant capital expenditure for compliance, or affect production.

Technological Obsolescence: The need for continuous R&D and process upgrades to remain competitive in a rapidly evolving chemical landscape.

Foreign Exchange Fluctuations: Exposure to currency risks due to import of raw materials or export of finished products.

Management & Ownership

Resonance Specialties Ltd. is a promoter-driven company, which is common in India. The promoter group typically holds a significant stake, indicating a long-term commitment to the business. Management quality can be assessed by their strategic decisions, focus on R&D, capacity expansion plans, and corporate governance practices. The promoter holding provides stability but also means decisions are often concentrated.

Outlook

Resonance Specialties operates in the resilient and growing Indian specialty chemicals sector, benefiting from a diversified end-user base (pharma, agro, plastics). Its niche focus on products like Piperazine derivatives provides a degree of insulation from broader commodity cycles and fosters strong customer relationships, which can be a source of stable revenue. However, the company faces inherent risks associated with the chemical industry, including the volatility of raw material prices, intense competition, and stringent environmental regulations that necessitate continuous investment in compliance and R&D. Future growth will be contingent on successfully navigating these challenges, executing planned capacity expansions, diversifying its product portfolio, and capitalizing on the structural growth drivers of its key end-user industries both domestically and internationally.

Resonance Specialtie Share Price

Live · BSE · Inception: 1989
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Resonance Specialtie Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 16 17 18 18 24 21 22 23 24 33
Other Income 0 0 0 0 0 0 0 0 1 1
Total Income 17 18 18 19 24 22 22 23 25 33
Total Expenditure 15 15 16 16 20 19 19 20 19 25
Operating Profit 1 2 3 2 4 3 3 4 6 8
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 -1 0 0 -0 0 0 0 0 0
Profit Before Tax 1 1 2 2 4 2 2 3 6 8
Provision for Tax 0 0 0 1 1 1 1 1 1 2
Profit After Tax 1 1 2 1 3 2 2 3 5 6
Adjustments -0 -0 -0 0 0 0 0 0 0 0
Profit After Adjustments 1 1 2 1 3 2 2 3 5 6
Adjusted Earnings Per Share 0.6 0.5 1.6 1 2.6 1.4 1.4 2.2 4 5

Resonance Specialtie Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 39 34 36 40 56 70 76 59 55 78 90 102
Other Income 0 1 1 1 2 2 1 2 1 1 2 2
Total Income 39 35 37 42 58 72 77 60 56 79 92 103
Total Expenditure 36 32 35 35 48 56 59 52 50 67 76 83
Operating Profit 3 3 2 6 10 16 18 8 6 12 16 21
Interest 1 0 1 1 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 2 1 1 2 1 0
Exceptional Income / Expenses 0 0 -0 -0 -1 0 0 0 0 -1 0 0
Profit Before Tax 2 1 0 5 7 15 16 7 4 9 14 19
Provision for Tax 0 0 1 2 1 4 4 2 1 2 4 5
Profit After Tax 1 1 -1 3 6 11 12 5 3 7 10 16
Adjustments 0 0 0 -0 0 0 0 0 0 0 0 0
Profit After Adjustments 1 1 -1 3 6 11 12 5 3 7 10 16
Adjusted Earnings Per Share 1 0.9 -0.6 2.8 4.8 9.1 10.7 4.3 2.6 5.7 9 12.6

Resonance Specialtie Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 23 24 23 26 31 41 52 56 57 64 73
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 2 3 2 1
Other Non-Current Liabilities 1 1 2 2 2 2 2 2 2 2 2
Total Current Liabilities 8 15 12 10 9 12 3 7 11 8 16
Total Liabilities 32 40 37 38 41 55 57 66 74 76 92
Fixed Assets 14 15 15 14 14 16 14 20 23 21 21
Other Non-Current Assets 1 2 2 2 3 1 1 1 1 2 5
Total Current Assets 17 23 20 22 24 38 42 45 50 52 67
Total Assets 32 40 37 38 41 55 57 66 74 76 92

Resonance Specialtie Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 1 1 1 1 2 2 6 9 4 0 0
Cash Flow from Operating Activities 3 1 2 5 1 4 13 -8 4 -3 17
Cash Flow from Investing Activities -1 -3 -1 -1 -2 -1 -9 3 -7 4 -15
Cash Flow from Financing Activities -2 2 -1 -4 1 0 -2 1 0 -1 -2
Net Cash Inflow / Outflow 0 -0 0 1 1 3 3 -4 -2 -0 -0
Closing Cash & Cash Equivalent 1 1 1 2 2 6 9 4 2 0 0

Resonance Specialtie Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 1.03 0.89 -0.6 2.78 4.77 9.12 10.71 4.33 2.57 5.69 9.01
CEPS(Rs) 2 1.81 0.39 3.56 5.57 9.97 12.22 5.61 3.83 7.04 10.16
DPS(Rs) 0 0 0 0 1 1 1 1 0 1 1
Book NAV/Share(Rs) 14.77 15.88 15.27 18.05 21.57 30.35 40 43.37 46.63 52.28 60.27
Core EBITDA Margin(%) 7.29 5.41 1.66 10.62 12.17 18.31 19.7 10.36 8.71 13.7 15.61
EBIT Margin(%) 5.21 4.81 1.76 11.65 11.41 19.08 19.23 10.57 7.76 11.94 15.95
Pre Tax Margin(%) 3.96 3.75 0.34 10.47 10.86 18.7 19.15 10.41 7.17 11.41 15.59
PAT Margin (%) 2.88 2.77 -1.79 7.05 8.64 13.52 14.54 7.6 5.37 8.44 11.52
Cash Profit Margin (%) 5.57 5.63 1.16 9.05 10.08 14.78 16.59 9.84 8 10.44 13
ROA(%) 3.56 2.85 -1.81 8.54 13.89 21.98 22.19 8.16 4.25 8.79 12.37
ROE(%) 7.24 5.8 -3.86 16.66 24.08 35.11 30.44 10.39 5.71 11.5 16
ROCE(%) 11.37 8.62 3.14 25.29 31.51 48.33 39.75 14.14 7.79 15.31 21.31
Receivable days 76.13 70.95 66.07 57.12 39.24 36.46 37.82 56.93 84.68 83.71 73.33
Inventory Days 68.54 106.26 110.4 75.54 63.74 70.23 60.6 96.41 151.64 115.05 122.4
Payable days 119.03 199.93 165.24 130.07 116.55 107.26 72.52 84.83 103.79 86.84 81.7
PER(x) 19.28 45.44 0 7.31 5.29 13.76 16.47 17.9 35.08 11.79 8.65
Price/Book(x) 1.35 2.54 1.85 1.12 1.17 4.13 4.41 1.79 1.93 1.28 1.29
Dividend Yield(%) 0 0 0 0 3.96 0.8 0.57 1.29 0 1.49 1.28
EV/Net Sales(x) 0.62 1.47 0.99 0.54 0.48 1.99 2.57 1.49 1.92 1.03 1.01
EV/Core EBITDA(x) 7.34 17.64 19.14 3.5 2.81 8.84 10.78 10.37 18.46 6.86 5.81
Net Sales Growth(%) 2.4 -12.16 5.2 11.96 39.43 25.21 7.78 -22.36 -5.97 40.7 15.99
EBIT Growth(%) 10.15 -17.39 -61.75 676.45 37.42 104.19 10.1 -57.46 -38.34 116.54 54.9
PAT Growth(%) -6.63 -13.83 -167.63 561.68 71.86 91.08 17.44 -59.54 -40.65 121.2 58.32
EPS Growth(%) -6.63 -13.84 -167.63 561.68 71.86 91.08 17.44 -59.54 -40.65 121.2 58.32
Debt/Equity(x) 0.11 0.22 0.19 0 0.02 0.03 0 0.04 0.08 0.05 0.03
Current Ratio(x) 2.03 1.58 1.71 2.28 2.78 3.12 12.52 6.7 4.32 6.76 4.12
Quick Ratio(x) 1.08 0.65 0.87 1.35 1.21 1.75 9.02 3.23 2.33 3.36 2.01
Interest Cover(x) 4.16 4.52 1.24 9.88 20.53 51.15 238.42 65.09 13.11 22.49 45.09
Total Debt/Mcap(x) 0.08 0.09 0.1 0 0.02 0.01 0 0.02 0.04 0.04 0.02

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +15% +15% +5% +9%
Operating Profit CAGR +33% +26% 0% +18%
PAT CAGR +43% +26% -2% +26%
Share Price CAGR +107% +28% -2% +16%
ROE Average +16% +11% +15% +14%
ROCE Average +21% +15% +20% +21%

Resonance Specialtie Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 54.25 %
FII 0 %
DII (MF + Insurance) 1.55 %
Public (retail) 44.2 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 54.2554.2554.2554.2554.2554.2554.2554.2554.2554.25
FII 0000000000
DII 0.030.030.030.030.030.030.030.031.551.55
Public 45.7245.7245.7245.7245.7245.7245.7245.7244.244.2
Others 0000000000
Total 100100100100100100100100100100

Resonance Specialtie Peer Comparison

Chemicals Edit Columns

Resonance Specialtie Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Resonance Specialtie Pros & Cons

Pros

  • Debtor days have improved from 86.84 to 81.7days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 11% over the last 3 years.
  • The company has delivered a poor profit growth of -1% over past five years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp